Cesarean Anesthesia Blood Gas
Effects of Spinal and General Anesthesia Techniques on Maternal-Fetal Blood Gas Gradients and Fetal Carboxyhemoglobin Levels in Cesarean Delivery: A Prospective Observational Cohort Study
This prospective observational cohort study will evaluate maternal and fetal blood gas parameters in women undergoing cesarean delivery under spinal or general anesthesia. Maternal venous blood samples will be obtained immediately before anesthesia induction, and umbilical arterial blood samples will be obtained after delivery and cord clamping. Blood gas parameters, including pH, pCO2, pO2, bicarbonate, base excess, lactate, and fetal carboxyhemoglobin levels, will be compared between the spinal and general anesthesia groups. The study will also evaluate maternal-fetal blood gas gradients, Apgar scores, neonatal intensive care requirements, and the relationship between smoking exposure and fetal carboxyhemoglobin levels.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Ali KAHVECİOĞLU, MD
- Telefonnummer: +90 5549134317
- E-Mail: ali.kahveci92@gmail.com
Studienorte
-
-
Istanbul
-
Istanbul, Istanbul, Türkei (türkiye), 59050
- Rekrutierung
- Bağcılar Training and Research Hospital
-
Kontakt:
- Ali KAHVECİOĞLU, MD
- Telefonnummer: +90 5549134317
- E-Mail: ali.kahveci92@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Pregnant women undergoing cesarean delivery at the Obstetrics and Gynecology Clinic of Bagcilar Training and Research Hospital. The study is a prospective observational cohort comparing maternal and fetal blood gas parameters and fetal carboxyhemoglobin levels according to the observed anesthesia technique (spinal or general anesthesia).
Beschreibung
Inclusion Criteria:
- Adult women undergoing cesarean delivery at the study center.
- Patients receiving spinal or general anesthesia for cesarean delivery.
Exclusion Criteria:
- Patients who are not eligible for participation according to the study protocol.
- Patients in whom spinal anesthesia is converted to general anesthesia because of inadequate spinal block and pain during surgery.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
|---|---|
|
Spinal Anesthesia
Participants undergoing cesarean delivery who receive spinal anesthesia as the anesthesia technique. |
Observed anesthesia technique in women undergoing cesarean delivery. Participants received either spinal anesthesia or general anesthesia as part of routine clinical care; the anesthesia technique was not assigned by the study. |
|
General Anesthesia
Participants undergoing cesarean delivery who receive general anesthesia as the anesthesia technique. |
Observed anesthesia technique in women undergoing cesarean delivery. Participants received either spinal anesthesia or general anesthesia as part of routine clinical care; the anesthesia technique was not assigned by the study. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Umbilical artery pH
Zeitfenster: Immediately after delivery
|
Umbilical arterial pH measured after delivery and cord clamping. |
Immediately after delivery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Maternal venous pH
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous pH measured immediately before anesthesia induction. |
Immediately before anesthesia induction
|
|
Umbilical artery pCO2
Zeitfenster: Immediately after delivery
|
Umbilical arterial pCO2 measured after delivery and cord clamping. |
Immediately after delivery
|
|
Umbilical artery pO2
Zeitfenster: Immediately after delivery
|
Umbilical arterial pO2 measured after delivery and cord clamping. |
Immediately after delivery
|
|
Maternal venous pCO2
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous pCO2 measured immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Maternal venous pO2
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous pO2 measured immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Umbilical artery HCO3
Zeitfenster: Immediately after delivery
|
Umbilical arterial bicarbonate measured after delivery and cord clamping. |
Immediately after delivery
|
|
Maternal venous HCO3
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous bicarbonate measured immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Umbilical artery BE
Zeitfenster: Immediately after delivery
|
Umbilical arterial base excess measured after delivery and cord clamping |
Immediately after delivery
|
|
Maternal venous BE
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous base excess measured immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Umbilical artery lactate
Zeitfenster: Immediately after delivery
|
Umbilical arterial lactate measured after delivery and cord clamping |
Immediately after delivery
|
|
Maternal venous lactate
Zeitfenster: Immediately before anesthesia induction
|
Maternal venous lactate measured immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Umbilical artery FCOHb
Zeitfenster: Immediately after delivery
|
Fetal carboxyhemoglobin measured in umbilical arterial blood after delivery and cord clamping |
Immediately after delivery
|
|
Maternal venous FCOHb
Zeitfenster: Immediately before anesthesia induction
|
Maternal carboxyhemoglobin measured in venous blood immediately before anesthesia induction |
Immediately before anesthesia induction
|
|
Maternal-fetal pH gradient (ΔpH)
Zeitfenster: Immediately after delivery
|
Difference between maternal venous pH and umbilical arterial pH |
Immediately after delivery
|
|
Maternal-fetal pCO2 gradient (ΔpCO2)
Zeitfenster: Immediately after delivery
|
Difference between maternal venous pCO2 and umbilical arterial pCO2 |
Immediately after delivery
|
|
Maternal-fetal lactate gradient (Δlactate)
Zeitfenster: Immediately after delivery
|
Difference between maternal venous lactate and umbilical arterial lactate |
Immediately after delivery
|
|
Apgar score at 1 minute
Zeitfenster: 1 minute after birth
|
Apgar score assessed 1 minute after birth using the Apgar score (range, 0-10), with higher scores indicating better neonatal condition. |
1 minute after birth
|
|
Apgar score at 5 minutes
Zeitfenster: 5 minutes after birth
|
Apgar score assessed 5 minutes after birth using the Apgar score (range, 0-10), with higher scores indicating better neonatal condition. |
5 minutes after birth
|
|
Neonatal intensive care unit admission
Zeitfenster: During the immediate neonatal period
|
Requirement for admission to the neonatal intensive care unit after birth |
During the immediate neonatal period
|
|
Neonatal intubation
Zeitfenster: During the immediate neonatal period
|
Requirement for endotracheal intubation after birth |
During the immediate neonatal period
|
|
Maternal hypotension requiring treatment
Zeitfenster: From anesthesia induction until the end of surgery
|
Occurrence of maternal hypotension requiring pharmacologic treatment during cesarean delivery |
From anesthesia induction until the end of surgery
|
|
Maternal vasopressor requirement
Zeitfenster: From anesthesia induction until the end of surgery
|
Requirement for vasopressor administration for management of maternal hypotension during cesarean delivery |
From anesthesia induction until the end of surgery
|
|
Smoking exposure and fetal FCOHb
Zeitfenster: Immediately after delivery
|
Association between maternal smoking exposure status and fetal carboxyhemoglobin level measured in umbilical arterial blood |
Immediately after delivery
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Ali KAHVECİOĞLU, MD, University of Health Sciences, Bağcılar Training and Research Hospital
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- E-10840098-50.04-4657
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .